Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
Although many approaches have been developed for the treatment of hepatocellular carcinoma (HCC) that has both high incidence and high mortality especially in Asian countries, the prognosis of HCC patients is still dismal. Immunotherapy, particularly immune checkpoint inhibitors show encouraging eff...
Main Authors: | Qi Zhang, Yiwen Chen, Xueli Bai, Tingbo Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.590058/full |
Similar Items
-
Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas
by: Qi Zhang, et al.
Published: (2020-10-01) -
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
by: Liang Wen, et al.
Published: (2020-08-01) -
Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges
by: Qi Zhang, et al.
Published: (2020-10-01) -
Calreticulin couples with immune checkpoints in pancreatic cancer
by: Xing Huang, et al.
Published: (2020-03-01) -
Combinational therapy targeting the MET‐mTOR‐ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer
by: Xing Huang, et al.
Published: (2020-12-01)